

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of)	Group Art Unit: 4161	
)	Attorney Docket No. 269.PFUS	
Dahl et al.)	Examiner: Paul E. Zarek	
)		
Serial No: 10/540,782)	Filed: April 3, 2006	
Title: COMPOSITIONS AND METHODS FOR))
COMBINATION ANTIVIRAL THERAPY))

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

This is responsive to the Patent and Trademark Office Action mailed April 7, 2008 setting a one month period for response. Applicants submit herewith a Request for a Five Month Extension of Time, whereby the due date for response is October 7, 2008.

Restriction has been required between two inventions, that of Group I (claims 1-23) and Group II (claims 24-57). Applicants elect the invention of Group I with traverse. With regard to the election of species, applicants elect B = 5-fluorocytosine and R = H. Claims 1 – 9 and 11- 23 read on this species (emtricitabine is defined by these B and R groups).

Applicants respectfully request an Action on the merits.

Respectfully submitted,



Allan D. Kutzenco, Reg. No. 38,945

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Phone: (650) 522-6101
Fax: (650) 522-5575

Date: 10/1/08